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تشخيص وفحص وعالج العواقب السلبية لعمليات نقل الدم 
املبادئ التوجيهية اجملمع عليها لعمان
اأروى الرياميه، �شربيه الها�شميه، زينب العرمييه، لوي�س واد�شورث، عبد احلكيم الروا�س، مرت�شى اخلابوري، �شاهينا دار
abstract: The recognition and management of transfusion reactions (TRs) are critical to ensure patient safety 
during and after a blood transfusion. Transfusion reactions are classified into acute transfusion reactions (ATRs) 
or delayed transfusion reactions, and each category includes different subtypes. Different ATRs share common 
signs and symptoms which can make categorisation difficult at the beginning of the reaction. Moreover, TRs are 
often under-recognised and under-reported. To ensure uniform practice and safety, it is necessary to implement a 
national haemovigilance system and a set of national guidelines establishing policies for blood transfusion and for 
the detection and management of TRs. In Oman, there are currently no local TR guidelines to guide physicians and 
hospital blood banks. This paper summarises the available literature and provides consensus guidelines to be used 
in the recognition, management and reporting of ATRs. 
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امللخ�ص: إن لتشخيص وفحص وعالج العواقب السلبية لعمليات نقل الدم دورا حامسا يف احلفاظ على سالمة املريض يف أثناء عملية نقل الدم وبعدها. 
تقسم العواقب السلبية لنقل الدم إىل نوعني: نوع مبكر وأخر متأخر، ولكل نوع منهما أنواع فرعية خمتلفة. وتشرتك العواقب السلبية يف بعض األعراض 
مما قد جيعل تصنيفها عسريا عند بداية ظهورها. باإلضافة لذلك فان من الغالب عدم التعرف عليها واإلبالغ عنها بالصورة املطلوبة. ويف سبيل ارساء 
قواعد ممارسة آمنة وموحدة لعمليات نقل الدم فانه من الضروري تطبيق نظام وطين للمراقبة والتيقظ يف املستشفيات وبنوك الدم، ووضع مبادئ توجيهية 
جممع عليها لسياسات نقل الدم والكشف عن األعراض السلبية اليت قد تنتج عنها وطرق معاجلتها. وال يتواجد يف الوقت احلايل يف عمان قواعد ممارسة 
حملية يف هذا اجملال إلرشاد األطباء واملستشفيات وبنوك الدم. تلخص هذه الورقة األدبيات العلمية والطبية املنشورة يف هذا اجلانب، وتقرتح جمموعة من 
املبادئ التوجيهية اجملمع عليها لتستخدم يف متييز العواقب السلبية لنقل الدم وفحصها وعالجها واإلبالغ عنها.
مفتاح الكلمات: نقل الدم؛ سالمة الدم؛ ردود فعل نقل الدم؛ املبادئ التوجيهية للتخطيط الصحي؛ عمان.
Recognition, Investigation and Management of 
Acute Transfusion Reactions
Consensus guidelines for Oman
*Arwa Z. Al-Riyami,1 Sabria Al-Hashmi,2 Zainab Al-Arimi,3 Louis D. Wadsworth,4 Abdulhakim Al-Rawas,5 
Murtadha Al-Khabori,1 Shahina Daar6
Departments of 1Haematology and 5Child Health, Sultan Qaboos University Hospital, Muscat, Oman; 2Department of Haematology & Blood Transfusion, 
Royal Hospital, Muscat, Oman; 3Directorate of Blood Services, Ministry of Health, Muscat, Oman; 4Centre for Blood Research, University of British 
Columbia, Vancouver, British Columbia, Canada; 6Department of Haematology, College of Medicine & Health Sciences, Sultan Qaboos University, 
Muscat, Oman
*Corresponding Author e-mail: arwa.alriyami@gmail.com
A key aspect of patient safety during blood transfusions is to ensure that patients are monitored by staff trained in transfusion 
medicine and the recognition and management of 
transfusion reactions (TRs). Each organisation should 
have a local transfusion programme and guidelines 
for the administration of blood components and for 
reporting TRs. The true incidence of TRs is uncertain 
due to the wide variation in reporting rates.1 Reports 
from the Serious Hazard of Transfusion (SHOT) 
haemovigilance scheme in the UK suggest an incidence 
of serious TRs of 14/100,000 components transfused.2
Transfusion in Oman takes place at the secondary 
and tertiary healthcare settings. Blood is collected and 
prepared in the central blood bank and the hospitals. 
Pre-storage leukoreduction has not yet been universally 
implemented, although some institutions have 
introduced pre-storage and bedside leukoreduction. 
The lack of universal leukoreduction can result in an 
increased risk of a febrile non-haemolytic transfusion 
reaction (FNHTR), human leukocyte antigen (HLA) 
alloimmunisation, platelet refractoriness and possibly 
transfusion-related acute lung injury (TRALI).3 A 
uniform TR reporting form was implemented in 2007 
in Oman. However, there are no national guidelines, 
and the incidence of serious TRs remains unknown.
This article aims to provide a guide on the 
diagnosis, investigation, management and reporting 
of acute transfusion reactions (ATRs). These 
guidelines were produced by a working group of 
experts from four different institutions, including two 
haematopathologists, one pediatric haematologist, 
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from hospital, should also be instructed to report any 
symptoms that develop within the following 24-hour 
period of completion of the transfusion.4,5 
Different ATRs share common manifestations 
[Table 2], and some features can be obscured by 
the patient’s underlying condition or treatment. 
For example, fever is common in ATRs, but can 
represent febrile neutropaenia in a patient receiving 
chemotherapy. 
Scant data exist regarding the frequency of TRs in 
children, which may reflect the under-recognition or 
under-reporting of these reactions.6 Some researchers 
have observed increased adverse reactions in children 
over two years of age, who presented with allergic 
reactions more frequently than adults, while FNHTRs 
were more common in children aged 1–2 years.7,8 It 
is necessary to monitor the patients closely and to 
treat any manifestations (e.g. skin rashes, tachycardia, 
tachypnoea and irritability) that develop during a 
transfusion as an alert to a potential TR. 
Initial Clinical Assessment and 
Management
The main aim of the initial clinical assessment of ATRs 
is to identify patients with serious or life-threatening 
ATRs so as to provide timely and appropriate 
management. The management of ATRs should 
be guided by the manifestation and severity of the 
reaction, and be based on the most probable reaction 
subtype.1 
The first step to approaching any ATR is to stop the 
transfusion. The venous access needs to be maintained 
with normal saline while the patient is being assessed. 
The patient’s airway, breathing and circulation (ABC) 
need to be assessed next. If dyspnoea is present, the 
patient’s airway patency needs to be ensured and 
high-flow oxygen should be started. If the patient is 
wheezing without an upper airway obstruction being 
present, a physician should be informed immediately 
and the patient needs to be given a short-acting beta-2 
agonist (e.g. salbutamol). If the patient is hypotensive, 
they should be positioned in a recumbent position 
with their legs elevated. The patient’s details on their 
identity band should then be verified to ensure that 
they correspond exactly with those on the blood 
component compatibility label. Finally, the unit 
undergoing transfusion needs to be examined for its 
colour and for the presence of any unusual clumps, 
particulate matter or discolouration suggestive of 
bacterial contamination. After these steps have been 
undertaken, an initial assessment is made. The SAVE 
acronym summarises these common steps taken in the 
three adult haematologists, and an external reviewer 
with expertise in the field of transfusion medicine. 
Available literature and international guidelines on 
ATRs were reviewed and summarised. These guidelines 
were then customised to the local processes and to 
the therapeutic options available in Oman, including 
available laboratory investigations and medications. 
Classification of Transfusion 
Reactions
The general classification of TRs is based on the time 
between the transfusion and the onset of the reaction. 
The UK SHOT group has defined two types of TRs—
ATRs and delayed transfusion reactions (DTRs).1 
ATRs occur within 24 hours of the commencement 
of the transfusion while DTRs occur afterwards. 
TRs have various subtypes and further classification 
is based on the manifestations and the results of the 
investigations of the reaction. Table 1 describes the 
general classification and subtypes of TRs. ATRs will 
be reviewed in detail in these guidelines. 
Recognition of Transfusion 
Reactions
It is critical to monitor patients throughout a 
transfusion episode. The recognition of TRs may be 
improved by asking patients to report any signs and 
symptoms if these develop during the transfusion. 
As ATRs can present just hours after completing a 
transfusion, all patients, including those discharged 
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initial assessment and management of any TR [Figure 
1].
Subsequent decisions follow based on the severity 
of the ATR. It is very important to determine the 
severity of the reaction upon its onset in order to 
call for immediate medical help. In addition, any 
suspicion of ABO blood group incompatibility or 
bacterial contamination upon visual assessment of the 
unit or by the patient’s symptoms and manifestations 
should prompt an immediate call to the hospital blood 
bank. This step is undertaken so as to quarantine and 
possibly recall related components that may pose a 
risk to other recipients.
Once initial measures have been undertaken, 
additional therapies may be given and a decision needs 
to be made on whether to resume or discontinue the 
transfusion. Patients with mild febrile and allergic 
reactions, with no or limited changes in their vital 
signs and who are lacking other clinical symptoms, 
can have their transfusion resumed at a slower rate and 
under direct observation. However, if symptoms recur, 
the transfusion must be discontinued. Transfusions 
should not be resumed in patients with other types 
of ATR. Subsequent management depends on the 
patient’s signs and symptoms.
All TRs must be reported to the hospital blood 
bank regardless of the severity. A TR form should 
be completed and sent to the blood bank along with 
the implicated unit and post-transfusion samples. 
Units that were transfused within 24 hours prior to 
Table 2: Signs and symptoms of acute transfusion reactions
Sign/symptom Type of reaction Comments
Fever* FNHTR, AHTR, TRALI (with 
respiratory symptoms) or a septic 
reaction (bacterial contamination). This 
could also be unrelated to the blood 
transfusion. 
Can coexist with other symptoms 
such as chills, rigors, myalgia, nausea 
or vomiting, dyspnoea, hypotension 
(≥30 mmHg below the baseline) and 
tachycardia (heart rate of >40 bpm above 
the baseline).8 
Urticaria, hives or pruritus Allergic TR or anaphylaxis. Can be mild and localised or more severe 
with generalised urticaria.
Angioedema Allergic TR or anaphylaxis. May be preceded by a tingling sensation 
around the face and lips.
Dyspnoea or hypoxia TRALI, TACO, TAD or a severe allergic 
TR.
Severe dyspnoea without shock may 
occur in TRALI or TACO.
TAD is a diagnosis of exclusion. 
Therefore patients should be assessed for 
other causes of dyspnoea before making 
this diagnosis.
Stridor or bronchospasms Allergic TR/anaphylaxis or TACO. -
Pulmonary oedema TACO or TRALI. -
Hypotension† AHTR, severe allergic TR, anaphylaxis, 
septic reaction (bacterial contamination), 
TRALI, TACO, TAD or a hypotensive 
reaction (bradykinin-mediated 
hypotension). This could also be 
unrelated to the transfusion.
Isolated hypotensive reactions are a 
diagnosis of exclusion and occur within 
an hour of transfusion, in the absence of 
allergic or anaphylactic symptoms. These 
reactions usually require no or only 
minor interventions.1
Patients on ACE inhibitors are at 
risk. The risk is higher with bedside 
leukofiltration.
Pain FNHTR (generalised aches), AHTR (pain 
at the infusion site, abdomen, chest or 
loins) or an anaphylactic reaction (chest 
pain).
-
Severe anxiety or feelings of impending 
doom
AHTR or a septic reaction (bacterial 
contamination).
Mild anxiety is common in patients 
undergoing transfusions, especially 
for the first time. However, patients 
should be assessed for any TRs if anxiety 
develops.
Acute onset of bleeding DIC can be associated with AHTR or a 
septic reaction (bacterial contamination).
-
FNHTR = febrile non-haemolytic transfusion reaction; AHTR = acute haemolytic transfusion reaction; TRALI = transfusion-related acute lung 
injury; TR = transfusion reaction; TACO = transfusion-associated circulatory overload; TAD = transfusion-associated dyspnoea; DIC = disseminated 
intravascular coagulation.
*Defined as a temperature of ≥38 °C and a rise of 1–2 °C from the baseline;1 †Defined as a drop in systolic and/or diastolic blood pressure by >30 
mmHg and a systolic blood pressure of ≤80 mm.1
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FNHTRs are characterised by an oral temperature 
≥38 °C and a rise of ≥1 °C from the baseline without 
systemic symptoms. On the other hand, moderate/
severe reactions are defined by an oral temperature 
≥39 °C or a rise of ≥2 °C from the baseline and/or 
any rise in temperature accompanied with systemic 
signs or symptoms (e.g. chills, rigors, myalgia, nausea 
or vomiting). If the patient has anxiety, tachycardia, 
dyspnoea, back/chest pain, haemoglobinuria, oliguria 
or bleeding from the intravenous (IV) site, other 
differential diagnoses should be considered, including 
bacterial contamination, an acute haemolytic 
transfusion reaction (AHTR) and TRALI.
Management
Classic FNHTRs are transient, resolving 
with symptomatic intervention including the 
administration of antipyretics (such as paracetamol/
acetaminophen) or non-steroidal anti-inflammatory 
the reaction can be associated with the reaction, and 
should be retained if possible and sent to the blood 
bank. If there is suspicion of a septic reaction, bacterial 
cultures should be requested. Figure 1 summarises 
the steps to be undertaken in the event of an ATR and 
Table 3 details the steps to be undertaken after the 
initial assessment is performed.




FNHTRs result from the patient’s reaction to donor 
white blood cells or to biological response modifiers in 
the component.9 Pre-storage leukoreduction reduces 
the rate of FNHTRs.10 Patients may present with 
either mild, moderate or severe reactions.1,11 Mild 
Figure 1: Approach to acute transfusion reactions.
ABC = airway, breathing and circulation; BP = blood pressure; TRALI = transfusion-related acute lung injury; TACO = transfusion-associated 
circulatory overload; TAD = transfusion-associated dyspnoea; TR = transfusion reaction; EDTA = ethylene-diamine-tetra-acetic acid.
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drugs (NSAIDs). Pethidine may be effective for 
patients with severe rigors. 
If the FNHTR is mild, the transfusion can 
be resumed after management and under direct 
observation of the patient.1,12 The TR needs to be 
reported to the blood bank, but post-transfusion 
samples and the implicated unit do not need to be sent. 
If the symptoms recur after restarting the transfusion 
in a mild FNHTR, or if the FNHTR is moderate to 
severe, the transfusion has to be discontinued. The 
TR must be reported to the blood bank by sending 
the TR reporting form along with the post-transfusion 
samples and the implicated unit(s). 
Prevention
Patients with significant and recurrent FNHTRs may 
benefit from oral paracetamol (acetaminophen) given 
one hour prior to subsequent transfusions.1 However, 
there is no firm evidence supporting this practice. If 
the fever persists despite premedication, leukoreduced 
red blood cells (RBCs) should be considered for 
future transfusions, if the implicated unit was not 
leukoreduced and if leukoreduction is locally available. 
If the fever persists or leukoreduction is unavailable, 
washed RBCs may be considered.1 
allergic transfusion reactions
Allergic TRs are more frequently seen with platelets 
and plasma than with RBCs.2 The cause of the 
majority of allergic reactions remains unexplained 
and it is not easy to identify the allergens causing 
the reaction. Evidence suggests that a history of 
allergies may predispose a patient to an allergic 
TR. However, both immunoglobulin A (IgA) and 
haptoglobin (Hp) deficiency should be suspected in 
the event of recurrent and/or severe allergic TRs. IgA-
deficient patients have a tendency to develop anti-IgA 
antibodies, which may cause severe and potentially 
fatal anaphylactic reactions if high titres of anti-IgA 
antibodies are present. These reactions occur early 
and can be fatal if not managed appropriately.13 Hp-
deficient individuals may experience anaphylaxis upon 
exposure to Hp in transfused products. There are data 
suggesting racial differences in the incidence of IgA- 
and Hp-deficiency.14 However, the incidence in Oman 
Table 3: Subsequent actions and procedures to be followed with acute transfusion reactions
Action Procedure
Notification • If the presumed ATR is severe or life-threatening, a doctor should be called immediately to assess the patient. 
The patient should be under direct observation until clinical improvments are noted. Reactions that fall under 
this category include:1
     - Life-threatening reactions that cause the airway, breathing and/or circulatory system to become 
        compromised.
     - Mismatched transfusion due to ABO blood group incompatibility identified by evidence of unit 
        mislabelling or intravascular haemolysis.
     - Septic reactions identified by evidence of bacterial contamination seen in the visual assessment of 
        the unit.
• If there is evidence of ABO blood group incompatibility or bacterial contamination, the hospital blood bank 
should be contacted immediately as other patients may be at risk.  
Specific 
management 





• In patients with mild reactions, the transfusion may be continued after appropriate treatment at a slower 
infusion rate and direct observation. Mild reactions are defined as an ATR with no or limited changes in the 
vital signs or other clinical symptoms of the patient. The two reactions that can be categorised this way are: 
     - Mild febrile reactions with a temperature ≥38 °C and a rise of 1–2 °C from baseline, without 
        other changes in vital signs.
     - Transient urticaria, pruritus and/or flushing, without other systemic symptoms.
• In patients with all other TR types, the transfusion should be discontinued. 
Reporting* • Fill out a TR reporting form and send it to the blood bank.
• Send the implicated component in a sealed plastic envelope to the laboratory with the transfusion set and 
clamped tubing. Do not send the bag with the infusion needle attached. Attach the TR reporting form to the 
outside of the sealed envelope.
• Retrieve all bags of products transfused whenever possible and send them to the blood bank. Products 
transfused anytime within the 24 hours preceding the onset of symptoms may be related to the TR symptoms 
encountered and should be retrieved and sent whenever possible.  
• Send the following patient samples to the blood bank (except in the case of mild reactions): 
     - One EDTA sample 
     - First voided post-transfusion urine sample (whenever feasible). 
• If a septic reaction (bacterial contamination) is suspected, blood cultures should be sent before starting the 
patient on any antibiotics. 
ATR = acute transfusion reaction; TR = transfusion reaction; EDTA = ethylene-diamine-tetra-acetic acid.
*All TRs must be reported to the hospital blood bank, regardless of severity.
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or prednisolone should be considered.14 Finally, a 
bronchodilator or nebulised beta-2 agonist (e.g. 
salbutamol) should be considered if bronchospasm 
develops. 
If a blood transfusion is still urgently needed 
and cannot be postponed, a different unit should be 
requested and infused as slowly as possible. 
Patients with moderate/severe or recurrent allergic 
TRs should be tested for IgA defiency. IgA deficiency 
is defined as the selective deficiency of IgA (<0.05 mg/
dL) in patients older than four years of age with other 
causes of hypogammaglobulinaemia having been 
excluded.15 The results should be interpreted with 
caution if a post-transfusion sample is tested. Isolated 
low IgA levels warrant testing for IgA antibodies.
Prevention
There is no evidence to support routine prophylaxis 
with antihistamines in patients with a previous history 
of mild allergic TRs and no studies have assessed 
the use of steroids.16 Patients with a previous mild 
allergic TR may receive further transfusions without 
premedication, and subsequent mild reactions can 
be managed by using systemic antihistamines and 
reducing the rate of the transfusion.1 However, it might 
be justifiable to premedicate patients with moderate 
to severe reactions with antihistamines. Moreover, 
subsequent transfusions must be performed in settings 
where patients can be directly observed by trained 
staff and where resuscitation facilities are available.1 
Washed RBCs are indicated in patients with severe 
or recurrent allergic TRs. However, washing platelet 
units has its own limitations and is not available in 
Oman.13 IgA-deficient patients with IgA antibodies and 
a history of TRs should receive RBC units donated by 
IgA-deficient donors as the first choice of treatment, or 
thoroughly washed RBCs as a second choice whenever 
feasible. Plasma and platelets should also be from 
IgA-deficient donors.1,17 In view of the lack of an IgA-
deficient donor database in Oman, thoroughly washed 
components should be requested as the most feasible 
option. However, urgent transfusions should not be 
withheld if washed components are not immediately 
available. That being said, the facilities and skills to 
manage severe allergic TRs must be present.1 
anaphylaxis
Anaphylaxis is a severe life-threatening systemic 
hypersensitivity characterised by rapidly developing 
airway, breathing and/or circulation compromises, 
usually associated with skin and mucosal 
changes.1 Patients may have bronchospasms, stridor, 
angioedema, urticaria, hypotension or other symptoms. 
This reaction shares a common pathophysiology with 
allergic TRs. Anaphylactic shock has rarely been 
is unknown.
Allergic reactions are subclassified as mild or 
moderate to severe. Mild reactions are defined as 
localised mild skin rashes/urticaria in the absence 
of other symptoms. Moderate to severe reactions 
are defined as severe urticarial reactions with wide-
spread lesions and/or bronchospasms, angioedema 
or respiratory compromise. Another possible sign 
is hypotension which, if present, should suggest the 
possibility of impending anaphylactic shock. Urticarial 
rashes may also be associated with pruritus, erythema, 
flushing, nausea/vomiting, abdominal cramps or 
diarrhoea.
Management
The management of allergic TRs depends on the 
severity of the reaction. As for all TRs, the first step 
is to stop the transfusion. For mild allergic TRs, 
practitioners should consider systemic antihistamines 
such as chlorphenamine.1 If symptoms improve with 
these initial measures, and in the absence of other 
symptoms, the transfusion may be resumed at a lower 
infusion rate after consultation with the physician and 
under direct observation.1,11 If the symptoms persist or 
recur despite the above measures, the transfusion must 
be terminated. The TR should still be reported to the 
blood bank, whether the transfusion was continued or 
terminated. However, post-transfusion samples and 
the implicated unit do not need to be sent.
In cases of moderate to severe allergic TRs, 
the transfusion should be halted immediately and 
a physician notified urgently. The patient’s ABC 
should be assessed and, if necessary, interventions 
should commence. Adrenaline (1:1000 dilution) 
should be administered immediately. Although both 
intramuscular (IM) and IV injections can be given, IM 
injections are more effective and circumvent any delay 
in establishing venous access. Adrenaline should not 
be withheld in thrombocytopenic patients or patients 
with coagulopathy. The dose can be repeated if needed 
at 5-min intervals depending on the patient’s blood 
pressure, pulse and respiratory status. 
After administration of the adrenaline, the patient 
should be placed in a recumbent position with the 
lower extremities elevated. Oxygen (O2) should be 
administered via facemask at 8–10 L/min. Two large-
bore IV cannulae should be inserted (14–16 gauges 
for adults and 20–22 gauges for paediatric patients). 
Patients should be given chlorphenamine via IM or 
slow IV injection.
If the patient is hypotensive, a normal saline bolus 
of 10–20 mL/kg (500–1,000 mL in adults) should 
be administered over 15 mins. Repeated boluses 
may be required to maintain the blood pressure. 
If the symptoms are severe, methylprednisolone 
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reported in complement component 4 (C4)-deficient 
patients after blood transfusions.18,19
Management
The management of anaphylactic reactions is the same 
as for moderate to severe allergic reactions as outlined 
above. 
Prevention
Premedication with steroids and antihistamines 
should be considered to prevent recurrence in patients 
with a history of anaphylactic reactions. Subsequent 
transfusions should only be carried out where patients 
can be observed directly and where staff trained in 
managing anaphylaxis are available.1
septic reactions (bacterial 
contamination)
Bacterial contamination of a blood component can 
occur either at the time of donation (due to subclinical 
donor bacteremia or non-adherence to aseptic 
techniques during the phlebotomy) or during blood 
component preparation, storage or handling. This can 
cause a septic ATR when the component is tranfused to 
a recipient. Both Gram-negative and -positive bacteria 
have been implicated.12 Although these reactions 
can occur with any blood component, platelets are 
the most commonly implicated since they are stored 
at room temperature which allows faster bacterial 
growth.4 When the implicated unit is transfused, the 
patient rapidly develops acute manifestations.20 
Bacterial contamination should be considered if 
the patient presents with a moderate or severe fever 
defined as a temperature ≥39 °C or a temperature 
rise of ≥2 °C from baseline. Bacterial contamination 
should also be suspected if any fever is accompanied 
with systemic symptoms such as chills, rigors, severe 
hypotension, shock, dyspnoea, myalgia, nausea or 
vomiting.1 Bacterial contamination should also be 
considered if the fever is persistent or unresponsive to 
symptomatic measures.
Patients may also present with isolated 
hypotension. Other symptoms, such as pain in the 
chest, back, abdomen or transfusion site, may confuse 
this reaction with an AHTR.21 Symptoms may develop 
rapidly or within four hours of the transfusion.21 The 
severity of the reaction is influenced by the type of 
bacteria involved, bacterial load and the recipient’s 
clinical status. Shock and disseminated intravascular 
coagulation (DIC) can occur if a Gram-negative 
bacterially infected unit with high levels of endotoxin 
was transfused. There should be increased caution 
in patients receiving blood transfusions while under 
anaesthesia (where manifestations may be masked) in 
patients with underlying fevers and in those who have 
been pre-medicated with antipyretics, as they may not 
develop a high-grade temperature as a warning sign.
Management
The management of patients suspected of a septic 
reaction begins with halting the transfusion. 
The implicated unit should be inspected for any 
discolouration, abnormal particles, clumps or signs 
of leakage. If any of these are present, the hospital 
blood bank must be notified immediately so its staff 
may recall and quarantine any other components 
from the implicated donation. A TR form must be 
sent to the blood bank along with the patient’s post-
transfusion samples and the implicated unit(s). The 
implicated unit should be cultured for aerobic and 
anaerobic organisms. In addition, blood cultures 
should be drawn from the patient and broad-spectrum 
IV antibiotics should be started. Blood cultures from 
the implicated unit should be examined for aerobic 
and anaerobic organisms. If the cultures are positive, 
all related components must be discarded and further 
antibiotic coverage should be determined based on the 
organism identified. 
Prevention
Future transfusions do not require any precautions. 
However, if there is a high frequency of these 
reactions, then a critical review of the blood collection 
process and storage facilities is indicated. The routine 
visual inspection of any unit at the time of laboratory 
processing and at the bedside prior to blood transfusion 
is crucial. All personnel must be trained to perform 
these visual assessments. The normal appearance 
of a unit does not exclude bacterial contamination.1 
Therefore, if this type of reaction is clinically suspected, 
action must be undertaken as detailed above.
transfusion-related acute lung 
injury
TRALI is defined as noncardiogenic pulmonary 
oedema following blood transfusion. Although all 
blood components have been implicated in TRALI, 
frozen plasma is the most common.22 However, small 
volumes of plasma (e.g. in RBC units) can cause TRALI 
if there are high levels of HLA or human neutrophil 
antigen (HNA) antibodies in the implicated unit and 
the patient has susceptible risk factors. 
The diagnosis of TRALI must fulfill the following 
criteria: (1) acute respiratory distress during the 
transfusion or within six hours of completing the 
transfusion; (2) hypoxaemia, defined by partial 
pressure of O2 (PaO2) in arterial blood divided by 
the fraction of inspired O2 (FiO2) ≤300 mmHg, 
blood oxygen saturation (SPO2) <90% on room air or 
other clinical evidence of hypoxaemia; (3) bilateral 
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pressure ≤18 mmHg or central venous pressure ≤15 
mmHg; (5) no pre-existing acute lung injury (ALI), 
and (6) no temporal relationship to an alternative 
risk factor of ALI, including aspiration, severe 
sepsis, pneumonia, multiple fractures, pancreatitis, 
shock, cardiopulmonary bypass, burn injuries, toxic 
inhalation, lung contusion, drug overdose or near 
drowning.24 If the first five criteria are met but there 
is a temporal association with another risk factor for 
ALI, the case is categorised as possible TRALI.
The primary mechanism of TRALI is the 
accumulation and activation of neutrophils within 
the pulmonary vascular endothelium. There are 
two existing models of TRALI. The two-hit model 
supports the hypothesis that TRALI occurs due to 
the interaction of two factors. The first factor is an 
underlying condition (e.g. critical illness, surgery, 
mechanical ventilation or severe sepsis) that may result 
in neutrophil priming and adherence to the pulmonary 
endothelium.25 The second factor is a mediator within 
the transfused component which activates the primed 
neutrophils and endothelial cells, inducing capillary 
leakage and pulmonary oedema.23,26 This can be 
caused by donor HLA or HNA antibodies that target 
recipient antigens, or bioactive lipids and soluble 
CD40 ligands that accumulate during the storage of 
cellular components.27 The second model, known as 
the threshold model, is based on the hypothesis that 
both the recipient and transfusion factors act together 
to overcome a particular recipient’s threshold and 
induce TRALI.24,27
Manifestations of TRALI can occur during the 
transfusion or in the six hours after completion of 
the transfusion, although they usually occur within 
two hours.1,28 Dyspnoea with acute hypoxia usually 
dominates the clinical picture. Other features 
include tachycardia, rigors, fever, hypothermia and 
hypotension.28 TRALI remains a clinical diagnosis.29 
Although TACO is in the differential diagnosis, 
certain features help to differentiate TRALI from 
TACO [Table 4]. A clinical examination and CXR are 
crucial to rule out any evidence of cardiac overload. 
The severity of TRALI can range from mild, requiring 
supplemental O2, to severe, necessitating mechanical 
ventilation. With respiratory support, most patients 
with TRALI recover in 24–72 hours, however 5–25% 
of cases are fatal.30,31
Management
The management of suspected TRALI requires 
immediate cessation of the transfusion. The patient’s 
airway should be ensured, the arterial O2 saturation 
level obtained and high-flow O2 should be begun. 
Mechanical ventilation should be considered. The 
patient should be assessed clinically for cardiac 
pulmonary infiltrates on a frontal chest X-ray (CXR); 
(4) no evidence of transfusion-associated circulatory 
overload (TACO) with pulmonary arterial wedge 
Table 4: Helpful features in differentiating transfusion-





May occur in any 






May occur at 
any age, but 
characteristically 
occurs at >70 years
Type of 
component
Usually plasma or 
platelets
Any
Speed of onset During the 
transfusion or 
within six hours 
of completion, 




within six hours of 
completion of the 
transfusion
Dyspnoea Present Present
Fever Present Usually absent











































TRALI = transfusion-related acute lung injury; TACO = transfusion-
associated circulatory overload; JVP = jugular venous pressure; CXR = 
chest X-ray; ECHO = echocardiogram; BNP = B-natriuretic peptide.
*Decreased left ventricular function does not exclude TRALI.
Adapted from: Tinegate H, Birchall J, Gray A, Haggas R, Massey E, 
Norfolk D, et al. Guideline on the investigation and management of 
acute transfusion reactions: Prepared by the BCSH Blood Transfusion 
Task Force.1 and Vlaar AP, Juffermans NP. Transfusion-related acute 
lung injury: A clinical review.23
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overload and a CXR should be obtained. The rest of 
the management should be supportive. Although 
some case reports advocate the use of steroids, no 
evidence supports their use.16 The reaction must be 
reported to the blood bank to quarantine or recall 
the rest of components from the implicated donor 
and to make decisions regarding donor deferral. The 
donor deferral decision must be made by an expert in 
transfusion medicine. Currently, tests to investigate 
an implicated donor are not available in Oman, but 
should be considered whenever made available.
Prevention
No precautions are needed for future transfusions, 
providing that TACO has been ruled out. There 
are two groups of donors likely to be implicated 
in antibody-mediated TRALI: multiparous females 
and donors with a history of transfusions. In the 
light of this, some countries have undertaken policies 
which only accept male donors for plasma and platelet 
donations in order to minimise the risk of TRALI.11
transfusion-associated 
circulatory overload
TACO is a condition characterised by left ventricular 
failure and pulmonary oedema due to fluid overload. 
This occurs either during transfusion or within the 
following six hours, in transfusions with a rapid 
infusion rate or a high volume of transfused products. 
Risk factors include extremes of age (patients >60 
years or <3 years), pre-existing cardiac and/or renal 
dysfunction, transfusions after an acute myocardial 
infarction, plasma transfusions, pre-existing positive 
fluid balances in the 24 hours prior to the transfusion 
and large-volume transfusions.32,33
Patients present with acute respiratory distress, 
dyspnoea, cyanosis, orthopnea, hypoxia, increase in 
systolic blood pressure (>20 mmHg above the baseline) 
and signs of cardiac overload (jugular venous pressure 
elevation and bilateral crepitation).1 Patients tend to 
respond to diuretics and worsen with fluid boluses. A 
CXR will show pulmonary oedema and cardiomegaly 
and an echocardiogram will be abnormal. There is 
some evidence suggesting that B-type natriuretic 
peptide (BNP) is a sensitive and specific marker of 
TACO.30 Until further evidence is available, BNP levels 
should be used as an adjunct marker to other features 
of volume overload in confirming the diagnosis of 
TACO.
Management
In suspected cases of TACO, management should 
begin by stopping the transfusion. Practitioners 
should ensure a patent airway, obtain the arterial O2 
saturation level and start high-flow O2. Mechanical 
ventilation should be considered. In addition, cardiac 
overload should be assessed and a CXR obtained. 
Diuretics should be administered, such as furosemide 
via the IV route. 
Prevention
In order to prevent recurrence, pre- or mid-transfusion 
diuretics should be considered in patients with a prior 
history or risk factors of TACO. Transfusion should 
recommence one unit at a time, with the patient being 
assessed after each unit. In high-risk patients, the 
transfusion can be performed at a slow rate. In patients 
with congestive heart failure (CHF), the transfusion 
should be postponed if possible until the CHF is 
deemed to be under control. When a transfusion 
is needed during an episode of CHF, it is important 
to request a split RBC unit to reduce the volume of 
infused blood in the four-hour time frame.33
transfusion-associated 
dyspnoea
Transfusion-associated dyspnoea (TAD) is defined as 
any respiratory distress within 24 hours of transfusion 
that does not meet the criteria of TRALI, TACO or 
an allergic reaction and that cannot be explained by 
an underlying condition or any other known cause.34 
TAD remains a clinical diagnosis and a diagnosis of 
exclusion.
Management
TAD should be managed by stopping the transfusion 
immediately. Management is supportive, after the 
patient has been assessed for potential causes of 
dyspnoea, including an AHTR, allergic TR, TRALI or 
TACO. 
Prevention
No precautions are needed for future transfusions, 
provided that other transfusion-related causes of 
dyspnoea have been ruled out. 
acute haemolytic transfusion 
reactions 
An AHTR occurs secondarily to a mismatched 
transfusion due to ABO incompatibility. This can 
occur as a result of clerical error, improper sample 
labelling or an error in patient testing or identification. 
It can also occur as an anamnestic response caused by 
non-ABO antibodies in alloimmuised patients due to 
a prior pregnancy or transfusion. The latter can occur 
in alloimmunised patients with sickle cell disease, 
among others, who develop an anamnestic response 
of pre-existing antibodies following the transfusion of 
non-phenotype-matched RBC unit(s), leading to acute 
haemolysis. The binding of the antibodies to donor 
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testing in the blood bank must include an antibody 
screen. If the antibody screen is positive, antibody 
identification should be carried out. Units selected 
for the transfusion should be antigen-negative for the 
implicated antibody and must be serologically cross-
match compatible with the patient’s plasma using an 
indirect antiglobulin method. 
hypotensive reactions
Hypotensive reactions are defined as hypotensive 
episodes with an isolated fall in systolic blood pressure 
of ≥30 mm occurring during or within one hour 
of completing the transfusion and a systolic blood 
pressure ≤80 mm, without any symptoms to suggest 
an allergic or anaphylactic reaction, other types of 
ATRs or other causes hypotension (e.g. blood loss).1 
This reaction has been associated with bradykinin 
release upon exposure to filtered blood and a history 
of angiotensin-converting enzyme (ACE) inhibitors 
should therefore be checked.  
Management
In cases of hypotensive reactions, the transfusion 
should be stopped. The patient should be placed in a 
recumbent position with their legs elevated, or in the 
recovery position if they are unconscious or nauseated. 
Normal saline boluses should be administered via an 
IV route. The transfusion should not be restarted. The 
reaction should be reported and the patient should be 
investigated as per the TR reporting format. 
Prevention
In order to prevent further recurrence, patients 
should be given a trial of washed RBCs. In cases 
where ACE inhibitors have been implicated, halting 
the ACE inhibitors before a blood transfusion should 
be considered if clinically safe, otherwise alternative 
antihypertensives should be considered.1,12
Reporting Transfusion 
Reactions
The reporting of TRs to hospital blood banks is 
essential. It directs immediate action when haemolytic 
TRs, TRALI or septic reactions are suspected, and 
also contributes to the haemovigilance system. 
Reporting instances of TRs may prompt recall of 
related components from the same donation and may 
result in donor deferrals. For some reactions, action 
should be undertaken immediately so as to prevent 
harming other patients. The two classic reactions are 
haemolytic TRs and septic reactions.
The process of reporting TRs to the blood 
bank should follow the local procedures within an 
RBCs leads to RBC lysis, activation of complement 
and coagulation pathways and cytokine release. 
Complement activation induces haemolysis, while 
activation of the coagulation cascade and thrombin 
generation predisposes the patient to DIC. 
The most common presentation of an AHTR is 
significant fever and chills, defined as a sustained fever 
≥39 °C or a rise of ≥2 °C from baseline and/or a fever 
accompanied by systemic symptoms such as chills, 
rigors, myalgia, nausea or vomiting. Alternatively, 
fevers which are unresponsive to symptomatic 
measures should be considered as a sign of a possible 
AHTR.
The classic presenting features are intravascular 
haemolysis (e.g. a falling haemoglobin level with a 
positive direct antiglobulin test (DAT), a rise in serum 
lactate dehydrogenase and haemoglobinurea), pain 
at the infusion site, flank pain, feelings of impending 
doom, anxiety and facial flushing. Patients may also 
present with isolated hypotension. If this reaction is 
not recognised, patients can progress to acute renal 
failure, DIC and death. 
Management
The management of suspected AHTRs should begin 
by stopping the transfusion immediately, establishing 
a new IV line and starting 0.9% normal saline. Saline 
boluses should be given to maintain urine output. The 
attending physician should be notified immediately and 
urine alkalinisation should be considered in the event 
of renal failure. As soon as a reaction is suspected, the 
hospital blood bank should be immediately informed 
by telephone as well as via the regular reaction 
reporting procedures. This is crucial in order to 
quarantine and recall other components that could 
have been issued to other patients. A post-transfusion 
blood sample and the first voided urine sample should 
be collected and sent to the blood bank, along with the 
implicated unit and the TR report. Coagulation, renal 
and liver function tests should be considered.
Prevention
Prevention of AHTRs is heavily related to adherence 
to clinical and laboratory policies with regards to 
patient identification and testing. At the time of the 
blood order/request proper patient identification and 
bedside sample labelling is a necessity to avoid sample 
mislabelling. In addition, and prior to commencing the 
transfusion, proper verification of the patient’s identity, 
the unit compatibility label and the request details is 
critical to detect errors and any ABO incompatibility. 
This should be performed at the patient’s bedside 
and in the presence of two nurses. However, it is also 
crucial to remember that non-ABO antibodies can be 
implicated in an AHTR. Therefore, pre-transfusion 
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institution. However, there must be a standardised 
procedure in the blood banks on how to handle TR 
investigations. Reports should be reviewed by an 
expert in transfusion medicine in order to ensure 
a proper evaluation, management and the final 
classification of the reaction type.  
Laboratory Investigations
The primary work-up for samples suspected of 
causing a TR is standardised. All units returned to the 
blood bank should undergo a second visual check for 
labelling, integrity and any evidence of haemolysis or 
bacterial contamination. In the event of a suspected 
haemolytic or septic reaction, the blood bank should 
recall and quarantine any associated components. 
Reports of moderate or severe TRs should prompt 
testing to rule out AHTRs. This includes repeat ABO 
and rhesus (D) grouping of both the patient sample 
and the returned unit; repeat antibody screening of 
the pre- and post-transfusion samples; repeat cross-
matching of both samples with the returned unit, and 
the performance of a DAT on the post-transfusion 
blood sample.1 In addition, the first voided post-
transfusion urine sample should be assessed for the 
presence of haemoglobinuria. In addition to the above, 
and if there is any suspicion of bacterial contamination, 
blood cultures should be obtained from the patient and 
the implicated unit. A protocol should be established 
regarding the aseptic sampling of the components for 
cultures to minimise the risk of contamination. 
Other basic investigations to be considered for 
moderate and severe TRs include a complete blood 
count, a coagulation profile and renal and liver 
function tests. 
Haemovigilance
A haemovigilance scheme is a monitoring programme 
which ensure the safety of transfusions. It allows the 
evaluation of trends, identification of any practice 
concerns or training needs, the introduction of 
guidelines and the evaluation of corrective actions 
taken to reduce transfusion risks. Haemovigilance 
programmes have been developed in many countries 
and include either mandatory or voluntary reporting 
schemes. As part of a haemovigilance programme, a 
uniform and systematic method for the reporting and 
evaluation of TRs should be implemented. 
Haemovigilance programmes should be overseen 
locally within individual institutions by the hospital 
transfusion committees. In addition, a haemovigilance 
programme needs to exist at a national level and 
all reported TRs should be reviewed by a national 
haemovigilance committee.
Conclusion
The prompt recognition, management and reporting 
of TRs are important aspects in ensuring patient 
safety during and after transfusions. TRs may 
have overlapping manifestations and it is therefore 
imperative that medical personnel be aware of the 
different types of reactions that can occur. This 
requires the continuous education of all healthcare 
professionals involved in the transfusion process as 
well as the development of standardised procedures. 
This paper has summarised the available literature 
on the recognition and management of different 
ATRs in order to provide local consensus guidelines 
for Oman. A national haemovigilance programme is 
required to set standards as well as ensuring training 
requirements on the proper handling and management 
of these reactions. Once such a programme has been 
developed in Oman, these guidelines may be used as 
a comprehensive source of information and guidance.
appendix
A list of common medications that can be used for 
the management of different ATRs is available in the 
appendix after the references. This appendix should be 
used as a reference only. 
References
1. Tinegate H, Birchall J, Gray A, Haggas R, Massey E, Norfolk 
D, et al. Guideline on the investigation and management of 
acute transfusion reactions: Prepared by the BCSH Blood 
Transfusion Task Force. Br J Haematol 2012; 159:143–53. doi: 
10.1111/bjh.12017.
2. Knowles S, Cohen H, Watt A, Poles D, Jones H, Davies T, et al. 
Serious Hazards of Transfusion (SHOT): Annual Report 2010. 
From: www.shotuk.org/wp-content/uploads/2011/07/SHOT-
2010-Report.pdf  Accessed: Jan 2014.
3. Hillyer CD, Silberstein MD, Ness PM, Anderson KN. Blood 
Banking and Transfusion Medicine: Basic Principles and 
Practice. 1st ed. Oxford, UK: Churchill Livingstone. Pp. 265–
361.
4. Taylor C, Cohen H, Mold D, Jones H, Asher D, Cawley C, et al. 
Serious Hazards of Transfusion (SHOT): Annual 2009 Report. 
From: www.shotuk.org/wp-content/uploads/2010/03/SHOT-
Report-2008.pdf  Accessed: Jan 2014.
5. British Committee for Standards in Haematology. Guideline 
on the Administration of  Blood Components. From: www.
bcshguidelines.com/documents/Admin_blood_components_
bcsh_05012010.pdf  Accessed: Mar 2014.
6. Gauvin F, Lacroix J, Robillard P, Lapointe H, Hume H. 
Acute transfusion reactions in the pediatric intensive care 
unit. Transfusion 2006; 46:1899–908. doi: 10.1111/j.1537-
2995.2006.00995.x.
7. Slonim AD, Joseph JG, Turenne WM, Sharangpani A, Luban 
NL. Blood transfusions in children: A multi-institutional 
analysis of practices and complications. Transfusion 2008; 
Arwa Z. Al-Riyami, Sabria Al-Hashmi, Zainab Al-Arimi, Louis D. Wadsworth, Abdulhakim Al-Rawas, Murtadha Al-Khabori and 
Shahina Daar
Special Contribution | e317
Pp. 870–84.
23. Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: 
A clinical review. Lancet 2013; 382:984–94. doi: 10.1016/S0140-
6736(12)62197-7. 
24. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, 
McPhedran S, et al. Toward an understanding of transfusion 
related acute lung injury: Statement of a consensus panel. 
Transfusion 2004; 44:1774–89. doi: 10.1111/j.0041-
1132.2004.04347.x.
25. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute 
lung injury (TRALI). Brit J Haematol 2007; 136:788–99. doi: 
10.1111/j.1365-2141.2007.06492.x.
26. Silliman CC. The two-event model of transfusion-related acute 
lung injury. Crit Care Med 2006; 34:S124–31. doi: 10.1097/01.
CCM.0000214292.62276.8E.
27. Sachs UJ. Recent insights into the mechanism of transfusion-
related acute lung injury. Curr Opin Hematol 2011; 18:436–42. 
doi: 10.1097/MOH.0b013e32834bab01.
28. Skeate RC, Eastlund T. Distinguishing between transfusion 
related acute lung injury and transfusion associated circulatory 
overload. Curr Opin Hematol 2007; 14:682–7. doi: 10.1097/
MOH.0b013e3282ef195a.
29. Li G, Daniels CE, Kojicic M, Krpata T, Wilson GA, Winters 
JL, et al. The accuracy of natriuretic peptides (brain 
natriuretic peptide and N-terminal pro-brain natriuretic) in 
the differentiation between transfusion-related acute lung 
injury and transfusion-related circulatory overload in the 
critically ill. Transfusion 2009; 49:13–20. doi: 10.1111/j.1537-
2995.2008.01941.x.
30. Silliman CC, McLaughlin NJ. Transfusion-related acute 
lung injury. Blood Rev 2006; 20:139–59. doi: 10.1016/j.
blre.2005.11.001.
31. Sheppard CA, Lögdberg LE, Zimring JC, Hillyer CD. 
Transfusion-related acute lung injury. Hematol Oncol Clin 
North Am 2007; 21:163–76. doi: 10.1016/j.hoc.2006.11.011.
32. Growe GH, Petraszko TR, Bigham M. The approach taken to 
reducing the risk of transfusion related acute lung injury in 
Canada. Asian J Transfus Sci 2008; 2:84–6. doi: 10.4103/0973-
6247.42696.
33. Alam A, Lin Y, Lima A, Hansen M, Callum JL. The prevention 
of transfusion-associated circulatory overload. Transfusion 
Med Rev 2013; 27:105–12. doi: 10.1016/j.tmrv.2013.02.001.
34. International Haemovigilance Network/International Society 
for Blood Transfusion. Proposed Standard Definitions 
for Surveillance of Non-infectious Adverse Transfusion 
Reactions. From:  www.ihn-org.com/wp-content/uploads/2011 
/06/ISBT-definitions-for-non-infectious-transfusion-reactions.
pdf  Accessed: Mar 2014.
35. British Medical Association, Royal Pharmaceutical Society of 
Great Britain. British National Formulary. 66th ed. London: 
Pharmaceutical Press, 2013.
36. British Medical Association, Royal Pharmaceutical Society, 
Royal College of Paediatrics & Child Health, Neonatal & 
Paediatric Pharmacists Group. British National Formulary for 
Children, 2014–2015. London: Pharmaceutical Press, 2014.
48:73–80. doi: 10.1111/j.1537-2995.2007.01484.x.
8. Pedrosa AK, Pinto FJ, Lins LD, Deus GM. Blood transfusion 
reactions in children: Associated factors. J Pediatr (Rio J) 2013; 
89:400–6. doi: 10.1016/j.jped.2012.12.009. 
9. Heddle NM, Klama L, Meyer R, Walker I, Boshkov L, Roberts 
R, et al. A randomized controlled trial comparing plasma 
removal with white cell reduction to prevent reactions to 
platelets. Transfusion 1999; 39:231–8. doi: 10.1046/j.1537-
2995.1999.39399219278.x.
10. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder 
EL. Reduction of febrile but not allergic reactions to RBCs 
and platelets after conversion to universal prestorage 
leukoreduction. Transfusion 2004; 44:16–24. doi: 
10.1046/j.0041-1132.2004.00608.x.
11. British Columbia Provincial Blood Coordinating Office, 
Provincial Health Services Authority. Transfusion Medicine 
Medical Policy Manual. From: www.pbco.ca/index.
php?option=com_content&task=category&id=58&Itemid=96 
Accessed: May 2014.
12. Callum JL, Lin Y, Pinkerton PH. Bloody Easy 3: Blood 
Transfusions, Blood Alternatives and Transfusion Reactions: 
A Guide to Transfusion Medicine. 3rd ed.  Toronto, Canada: 
Ontario Regional Blood Coordinating Network, 2011.
13. Lerner NB, Refaai MA, Blumberg N. Red cell transfusion. In: 
Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, 
Prchal JT, eds. Williams Hematology. 8th ed. Columbus, Ohio: 
McGraw Hill Professional, 2010. Pp. 2287–300.
14. Hirayama F. Current understanding of allergic transfusion 
reactions: Incidence, pathogenesis, laboratory tests, prevention 
and treatment. Brit J Haematol 2013; 160:434–44. doi: 10.1111/
bjh.12150.
15. European Society for Immunodeficiencies. Definition of IgA 
Deficiency. From: www.esid.org/content/download/198/910/
file/IgA%20Deficiency.doc  Accessed: Mar 2014.
16. Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. 
A prospective, randomized, double-blind controlled trial 
of acetaminophen and diphenhydramine pretransfusion 
medication versus placebo for the prevention of transfusion 
reactions. Transfusion 2008; 48:2285–91. doi: 10.1111/j.1537-
2995.2008.01858.x.
17. Sandler SG. How I manage patients suspected of having had 
an IgA anaphylactic transfusion reaction. Transfusion 2006; 
46:10–13. doi: 10.1111/j.1537-2995.2006.00686.x.
18. Lambin P, Le Pennec PY, Hauptmann G, Desaint O, Habibi 
B, Salmon C. Adverse transfusion reactions associated with a 
precipitating anti-C4 antibody of anti-Rodgers specificity. Vox 
Sang 1984; 47:242–9. doi: 10.1111/j.1423-0410.1984.tb01592.x.
19. Westhoff CM, Sipherd BD, Wylie DE, Toalson LD. Severe 
anaphylactic reactions following transfusions of platelets 
to a patient with anti-Ch. Transfusion 1992; 32:576–9. doi: 
10.1046/j.1537-2995.1992.32692367205.x.
20. Blajchman M, Goldman M. Bacterial contamination of platelet 
concentrates: Incidence, significance, and prevention. Semin 
Hematol 2011; 38:20–6. doi: 10.1016/S0037-1963(01)90120-9.
21. Hewitt P. Bacterial contamination. In: Murphy MF, Pamphilon 
DH, Eds. Practical Transfusion Medicine. 3rd ed. Oxford, UK: 
Wiley-Blackwell, 2009. Pp. 146–52.
22. Wallis JP, Sachs UJH. Transfusion-related acute lung injury. 
In: Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss 
RG, Solheim BG, et al., Eds. Rossi’s Principles of Transfusion 
Medicine. 4th ed. Bethesda, Maryland: Wiley-Blackwell, 2009. 
Recognition, Investigation and Management of Acute Transfusion Reactions 
Consensus guidelines for Oman
e318 | SQU Medical Journal, August 2014, Volume 14, Issue 3
Appendix: List of common medications that can be used for the management of different acute transfusion reactions
Medication Adult doses35 Paediatric and adolescent doses36
Adrenaline, IM
[1:1000 dilution, 1 mg/mL]
0.5 mL (500 mcg)* <6 years: 0.15 mL (150 mcg)*
6–12 years: 0.3 mL (300 mcg)*
12–18 years: 0.5 mL (500 mcg)*
Only 0.3 mL (300 mcg) should be given if the 
adolescent is small or pre-pubertal
Chlorphenamine, PO 4 mg†
Maximum of 24 mg daily for adults 
and 12 mg daily for the elderly
1 month–2 years: 1 mg‡
2–6 years: 1 mg†
Maximum of 6 mg daily
6–12 years: 2 mg†
Maximum of 12 mg daily
12–18 years: 4 mg†
Maximum of 24 mg daily
Chlorphenamine, IM or slow IV 10 mg†
Maximum of 40 mg daily
1-6 months: 250 mcg/kg/dose§
Maximum of 2.5 mg per dose
6 months–6 years: 2.5 mg§
6–12 years: 5 mg§
12–18 years: 10 mg§ 
Furosemide 20–50 mg, via IM or slow IV 0.5–1.0 mg/kg, via IV only
Hydrocortisone, IM/IV 100–500 mg¶ <6 months: 25 mg¶
6 months–6 years: 50 mg¶
6–12 years: 100 mg¶
12–18 years: 200 mg¶
Paracetamol/acetaminophen, PO 500–1,000 mg†
Maximum of 4 g daily
10–15 mg/kg†
Maximum of 60 mg/kg/day daily
Paracetamol/acetaminophen, IV <50 kg: 10–15 mg/kg/dose†
Maximum of 60 mg/kg daily
>50 kg: 1,000 mg†
Maximum of 4 g daily
<10 kg: 7.5 mg/kg/dose†
Maximum of 30 mg/kg daily
10–50 kg: 10–15 mg/kg/dose†
Maximum of 60 mg/kg daily
Pethidine, slow IV 25–50 mg Not recommended
Salbutamol, nebulised 5 mg†† <5 years: 2.5 mg††
6–12 years: 2.5–5 mg††
12–18 years: 5 mg††
IM = intramuscular; PO = per os; IV = intravenous.
*Doses may be repeated if necessary at 5-min intervals according to the patient’s blood pressure, pulse and respiratory function.†Doses may be 
repeated every 4–6 hours.‡Doses may be repeated if required up to two times in 24 hours.§Doses may be repeated if required up to four times in 24 
hours.¶Doses may be repeated if required up to three times in 24 hours and adjusted as per the response.††Repeat at 20–30 min intervals as necessary.
